Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Blood Flow MRI for Monitoring Brain Tumors (Glioma)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2013 by Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
Beth Israel Deaconess Medical Center Identifier:
First received: February 20, 2012
Last updated: April 2, 2013
Last verified: April 2013

The investigators are studying the use of an advanced magnetic resonance imaging (MRI) technique for measuring blood flow into brain tumors. This technique does not use radioactive tracers, and it can provide high quality images that can be obtained in a standard MRI scanner.

Brain Tumors

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Blood Flow MRI for Monitoring of Glioma Angiogenesis

Resource links provided by NLM:

Further study details as provided by Beth Israel Deaconess Medical Center:

Estimated Enrollment: 125
Study Start Date: June 2006
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Detailed Description:

Our goals are:

  1. To compare the blood flow measured with this technique with measures of tumor blood vessel density in pieces of the tumor surgically removed as a normal part of clinical treatment. This will confirm a relationship between the imaging measurements and the microscopic characteristics of tumors.
  2. To compare the blood flow in tumors before therapy with the concentration of choline, an indicator of cell proliferation. This choline concentration can be measured with another MRI technique. This information will demonstrate the relationship between cell proliferation and blood supply and will also determine whether the choline measurement adds additional information that is clinically necessary.
  3. To determine the reproducibility of blood flow measurements in tumors. This is necessary to better understand the sensitivity of the technique to changes in flow caused by a treatment or changes in tumor vascularity.
  4. To monitor changes in blood flow after initial treatment. Since sometimes tumors can reappear, the repeated measures will help determine how useful this new imaging technique is at detecting such recurring tumors.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All subjects will be brain tumor patients recruited through the Brain Tumor Center at the Beth Israel Deaconess Medical Center.


Inclusion Criteria:

  • diagnosed with or are suspected of having a glioma

Exclusion Criteria:

  • contraindications to MRI which may include the following

    1. Pacemaker
    2. MRI incompatible metal implant
    3. Recently implanted vascular clip
    4. History of claustrophobia
    5. Metal fragment within the eye

Subjects who have received nonstandard therapy may be excluded if the therapy might alter tumor blood flow or other imaging characteristic.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01538264

Contact: Kelly Roth, BA 617-667-0290 ext 7-0290
Contact: Meaghan Fox, BS 617-667-5915 ext 7-5915

United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Kelly Roth, BA    617-667-0290 ext 7-0290   
Contact: Meaghan Fox, BS    617-667-5915 ext 7-5915   
Principal Investigator: David C Alsop, PhD         
Sub-Investigator: Rachel Scheidegger, PhD         
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Principal Investigator: David C Alsop, PhD Beth Israel Deaconess Medical Center
  More Information

No publications provided

Responsible Party: Beth Israel Deaconess Medical Center Identifier: NCT01538264     History of Changes
Other Study ID Numbers: 2006-P-000116, R01CA115745-05
Study First Received: February 20, 2012
Last Updated: April 2, 2013
Health Authority: United States: Institutional Review Board
United States: Federal Government

Additional relevant MeSH terms:
Brain Neoplasms
Brain Diseases
Central Nervous System Diseases
Central Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases
Nervous System Neoplasms processed this record on November 20, 2014